Synopsis
Synopsis
0
VMF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. 1h-benzimidazole, 2-(((4-(3-methoxypropoxy)-3-methyl-2-pyridinyl)methyl)sulfinyl)-, Sodium Salt
2. 2-((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methylsulfinyl)-1h-benzimidazole
3. Aciphex
4. Dexrabeprazole
5. E 3810
6. E3810
7. Ly 307640
8. Ly-307640
9. Ly307640
10. Pariet
11. Rabeprazole
12. Sodium, Rabeprazole
1. 117976-90-6
2. Rebeprazole Sodium
3. Pariet
4. Aciphex
5. Rabeprazole Sodium Salt
6. Dexrabeprazole Sodium
7. Rabeprazole (sodium)
8. (s)-rabeprazole Sodium Salt
9. Aciphex Sprinkle
10. Ly307640 Sodium
11. Sodium Rabeprazole
12. Rabeprazole Sodium [usan]
13. Idiazole
14. Rabeprazole Na
15. Chebi:8769
16. 171440-19-0
17. Ly-307640
18. E3810
19. E-3810 Sodium
20. Sodium;2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]benzimidazol-1-ide
21. Ly-307640 Sodium
22. 3l36p16u4r
23. 1h-benzimidazole, 2-(((4-(3-methoxypropoxy)-3-methyl-2-pyridinyl)methyl)sulfinyl)-, Sodium Salt
24. 2-(((4-(3-methoxypropoxy)-3-methyl-2-pyridyl)methyl)sulfinyl)benzimidazole Sodium Salt
25. Nsc-759270
26. Dsstox_cid_24205
27. Dsstox_rid_80118
28. Dsstox_gsid_44205
29. 1h-benzimidazole, 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]-, Sodium Salt (1:1)
30. Rabicip
31. Pepcia
32. Aciphex Sodium
33. Ly 307640 Sodium
34. Habeprazole Sodium
35. Sodium 2-((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methylsulfinyl)benzo[d]imidazol-1-ide
36. Sodium 2-({[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methyl}sulfinyl)benzimidazol-1-ide
37. Smr000550493
38. Cas-117976-90-6
39. Ncgc00159518-02
40. E 3810
41. Pariete
42. Unii-3l36p16u4r
43. Pariprazole Sodium
44. Dexrabeprazolesodium
45. Rebeprazole Sodium;
46. Aciphex (tn)
47. Pariet (tn)
48. Rebeprazole Sodium Salt
49. Rabeprazole Sodium- Bio-x
50. Mls001165734
51. Mls006010621
52. Schembl140494
53. Rabeprazole Na [vandf]
54. Chembl1200930
55. Dtxsid3044205
56. Rabeprazole Sodium [jan]
57. Hy-b0656a
58. Rabeprazole Sodium (jp17/usp)
59. Ex-a176
60. Hms2093h10
61. Hms2231e04
62. Hms3373b05
63. Rabeprazole Sodium [mart.]
64. Bcp06639
65. Rabeprazole Sodium [usp-rs]
66. Rabeprazole Sodium [who-dd]
67. Tox21_111736
68. Tox21_302317
69. Ac-715
70. Bdbm50247881
71. Mfcd02092688
72. Rabeprazole Sodium Salt [mi]
73. S4665
74. Rabeprazole Sodium, >=98% (hplc)
75. Akos015895734
76. Akos015962116
77. Akos025310160
78. Tox21_111736_1
79. Am81231
80. Ccg-213574
81. Ccg-268423
82. Nsc 759270
83. Rabeprazole Sodium [orange Book]
84. Ncgc00159518-05
85. Ncgc00255838-01
86. Rabeprazole Sodium [ep Monograph]
87. As-13338
88. Br167318
89. Rabeprazole Sodium [usp Monograph]
90. Ft-0631090
91. Ft-0689461
92. R0115
93. C07865
94. D00724
95. F17418
96. 976r906
97. Sr-01000799133
98. J-010726
99. Q-201655
100. Sr-01000799133-2
101. Q27108142
102. [2-[[4-(3-methoxypropoxy)-3-methyl-2-pyridyl]methylsulfinyl]benzimidazol-1-yl]sodium
103. Sodium;2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]-1h-benzimidazole
104. 1h-benzimidazole,2-[[[4-(3-methoxypropoxy)- 3-methyl-2-pyridinyl]methyl]sulfinyl]-,sodium Salt
105. 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]-1h-benzimidazole, Sodium Salt
106. Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide
| Molecular Weight | 381.4 g/mol |
|---|---|
| Molecular Formula | C18H20N3NaO3S |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 8 |
| Exact Mass | 381.11230696 g/mol |
| Monoisotopic Mass | 381.11230696 g/mol |
| Topological Polar Surface Area | 81.5 Ų |
| Heavy Atom Count | 26 |
| Formal Charge | 0 |
| Complexity | 446 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 4 | |
|---|---|
| Drug Name | Aciphex |
| PubMed Health | Rabeprazole (By mouth) |
| Drug Classes | Antiulcer, Gastric Acid Secretion Inhibitor |
| Drug Label | The active ingredient in ACIPHEX Delayed-Release Tablets is rabeprazole sodium, a substituted benzimidazole that inhibits gastric acid secretion. Rabeprazole sodium is known chemically as 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl]sulfiny... |
| Active Ingredient | Rabeprazole sodium |
| Dosage Form | Tablet, delayed release |
| Route | oral; Oral |
| Strength | 20mg |
| Market Status | Prescription |
| Company | Eisai; Eisai Medcl Res |
| 2 of 4 | |
|---|---|
| Drug Name | Rabeprazole sodium |
| Drug Label | The active ingredient in ACIPHEX Delayed-Release Tablets is rabeprazole sodium, a substituted benzimidazole that inhibits gastric acid secretion. Rabeprazole sodium is known chemically as 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl]sulfiny... |
| Active Ingredient | Rabeprazole sodium |
| Dosage Form | Tablet, delayed release |
| Route | Oral |
| Strength | 20mg |
| Market Status | Prescription |
| Company | Mylan Pharms; Kremers Urban Dev; Teva Pharms Usa; Torrent Pharms; Lupin; Dr Reddys Labs |
| 3 of 4 | |
|---|---|
| Drug Name | Aciphex |
| PubMed Health | Rabeprazole (By mouth) |
| Drug Classes | Antiulcer, Gastric Acid Secretion Inhibitor |
| Drug Label | The active ingredient in ACIPHEX Delayed-Release Tablets is rabeprazole sodium, a substituted benzimidazole that inhibits gastric acid secretion. Rabeprazole sodium is known chemically as 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl]sulfiny... |
| Active Ingredient | Rabeprazole sodium |
| Dosage Form | Tablet, delayed release |
| Route | oral; Oral |
| Strength | 20mg |
| Market Status | Prescription |
| Company | Eisai; Eisai Medcl Res |
| 4 of 4 | |
|---|---|
| Drug Name | Rabeprazole sodium |
| Drug Label | The active ingredient in ACIPHEX Delayed-Release Tablets is rabeprazole sodium, a substituted benzimidazole that inhibits gastric acid secretion. Rabeprazole sodium is known chemically as 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl]sulfiny... |
| Active Ingredient | Rabeprazole sodium |
| Dosage Form | Tablet, delayed release |
| Route | Oral |
| Strength | 20mg |
| Market Status | Prescription |
| Company | Mylan Pharms; Kremers Urban Dev; Teva Pharms Usa; Torrent Pharms; Lupin; Dr Reddys Labs |
Treatment of duodenal ulcer, Treatment of gastric ulcer, Treatment of gastro-oesophageal reflux disease, Treatment of Helicobacter pylori in patients with peptic ulcer disease, Treatment of Zollinger-Ellison syndrome
Anti-Ulcer Agents
Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. This has included ANTIBIOTICS to treat HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS to reduce GASTRIC ACID secretion; and ANTACIDS for symptomatic relief. (See all compounds classified as Anti-Ulcer Agents.)
Proton Pump Inhibitors
Compounds that inhibit H(+)-K(+)-EXCHANGING ATPASE. They are used as ANTI-ULCER AGENTS and sometimes in place of HISTAMINE H2 ANTAGONISTS for GASTROESOPHAGEAL REFLUX. (See all compounds classified as Proton Pump Inhibitors.)

API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
27
PharmaCompass offers a list of Rabeprazole Sodium API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Rabeprazole Sodium manufacturer or Rabeprazole Sodium supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Rabeprazole Sodium manufacturer or Rabeprazole Sodium supplier.
PharmaCompass also assists you with knowing the Rabeprazole Sodium API Price utilized in the formulation of products. Rabeprazole Sodium API Price is not always fixed or binding as the Rabeprazole Sodium Price is obtained through a variety of data sources. The Rabeprazole Sodium Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A AC-715 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of AC-715, including repackagers and relabelers. The FDA regulates AC-715 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. AC-715 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of AC-715 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A AC-715 supplier is an individual or a company that provides AC-715 active pharmaceutical ingredient (API) or AC-715 finished formulations upon request. The AC-715 suppliers may include AC-715 API manufacturers, exporters, distributors and traders.
click here to find a list of AC-715 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A AC-715 DMF (Drug Master File) is a document detailing the whole manufacturing process of AC-715 active pharmaceutical ingredient (API) in detail. Different forms of AC-715 DMFs exist exist since differing nations have different regulations, such as AC-715 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A AC-715 DMF submitted to regulatory agencies in the US is known as a USDMF. AC-715 USDMF includes data on AC-715's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The AC-715 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of AC-715 suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The AC-715 Drug Master File in Japan (AC-715 JDMF) empowers AC-715 API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the AC-715 JDMF during the approval evaluation for pharmaceutical products. At the time of AC-715 JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of AC-715 suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a AC-715 Drug Master File in Korea (AC-715 KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of AC-715. The MFDS reviews the AC-715 KDMF as part of the drug registration process and uses the information provided in the AC-715 KDMF to evaluate the safety and efficacy of the drug.
After submitting a AC-715 KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their AC-715 API can apply through the Korea Drug Master File (KDMF).
click here to find a list of AC-715 suppliers with KDMF on PharmaCompass.
A AC-715 CEP of the European Pharmacopoeia monograph is often referred to as a AC-715 Certificate of Suitability (COS). The purpose of a AC-715 CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of AC-715 EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of AC-715 to their clients by showing that a AC-715 CEP has been issued for it. The manufacturer submits a AC-715 CEP (COS) as part of the market authorization procedure, and it takes on the role of a AC-715 CEP holder for the record. Additionally, the data presented in the AC-715 CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the AC-715 DMF.
A AC-715 CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. AC-715 CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of AC-715 suppliers with CEP (COS) on PharmaCompass.
A AC-715 written confirmation (AC-715 WC) is an official document issued by a regulatory agency to a AC-715 manufacturer, verifying that the manufacturing facility of a AC-715 active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting AC-715 APIs or AC-715 finished pharmaceutical products to another nation, regulatory agencies frequently require a AC-715 WC (written confirmation) as part of the regulatory process.
click here to find a list of AC-715 suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing AC-715 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for AC-715 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture AC-715 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain AC-715 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a AC-715 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of AC-715 suppliers with NDC on PharmaCompass.
AC-715 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of AC-715 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right AC-715 GMP manufacturer or AC-715 GMP API supplier for your needs.
A AC-715 CoA (Certificate of Analysis) is a formal document that attests to AC-715's compliance with AC-715 specifications and serves as a tool for batch-level quality control.
AC-715 CoA mostly includes findings from lab analyses of a specific batch. For each AC-715 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
AC-715 may be tested according to a variety of international standards, such as European Pharmacopoeia (AC-715 EP), AC-715 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (AC-715 USP).